STAT

APRIL 14, 2024

As diligent taxpayers breathe a sigh of relief that the hassle of filing their tax forms is over for another year, the Internal Revenue Service continues to let most U.S. hospitals pay nothing in federal taxes. It’s time for Congress to take a hard look at the IRS’s hand in health care. The agency uses a vague “community benefit” standard to liberally grant tax-exempt status to so-called nonprofit hospitals even as many of them are financially taking advantage of sick

Hospitals 364

Hospitals 364

ID Stewardship

APRIL 14, 2024

In this article a comparison of Rebyota versus Vowst is provided, to help learners differentiate these two fecal microbiota therapies. Authored by: Natalie Boyer, Pharm.D. Candidate 2025 Mentored by: Christina G. O’Connor, Pharm.D., PharmD, BCPS, BCIDP, AAHIV-M Disclaimer : This text and table is intended for use as a study tool to assist people learning pharmacotherapy of recurrent Clostridioides difficile infections (rCDI).

Hospitals 132

Hospitals Communication 132

Med Ed 101

APRIL 14, 2024

The fall 2024 BCPS exam will be changing compared to the spring version. The biggest shift in the BCPS exam is the content outline. In the YouTube video below, I outline the important changes and how this may impact your studying. We’ve updated our study materials for the fall exam specifically to ensure that they […] The post Fall 2024 BCPS Exam – Major Changes appeared first on Med Ed 101.

98

98

Express Pharma

APRIL 14, 2024

The FDA has approved Basilea Pharmaceutica’s advanced generation cephalosporin antibiotic, Zevtera (ceftobiprole medocaril), for the treatment of three major indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP).

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

pharmaphorum

APRIL 14, 2024

EMA review finds no link between GLP-1 agonists used to treat diabetes and obesity and thoughts of suicide or self-injury.

Diabetes 103

Diabetes 103

Express Pharma

APRIL 14, 2024

Granules India’s Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India has successfully completed the US Food and Drug Administration (FDA) inspection between April 8-12 2024, resulting in zero 483 observations. This audit was a Pre-Approval Inspection (PAI) and cGMP audit for Active Pharmaceutical Ingredients (APIs) and Formulations (FDs) for oncology and non-oncology products.

95

95

PharmaState Academy

APRIL 14, 2024

Get set for your success in GPAT journey with the Mock Test-14. Take Part Right Now! Note: You can participate only 1 time. Participation by using another name & email id will lead to disqualification. The winner will be announced after profile verification. Once you're a winner, you will not be considered for the prizes for another two months. Note: You can participate only 1 time.

52

52

Drug Patent Watch

APRIL 14, 2024

DEXILANT (dexlansoprazole) Takeda pharms usa Patent: 8,722,084 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.

59

59

PharmaState Academy

APRIL 14, 2024

Get set for your success in GPAT journey with the Mock Test-14. Take Part Right Now! Note: You can participate only 1 time. Participation by using another name & email id will lead to disqualification. The winner will be announced after profile verification. Once you're a winner, you will not be considered for the prizes for another two months. Note: You can participate only 1 time.

52

52

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for QVAR+REDIHALER Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. It is available from three suppliers.

59

59

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

PharmaState Academy

APRIL 14, 2024

Get set for your success in GPAT journey with the Mock Test-14. Take Part Right Now! Note: You can participate only 1 time. Participation by using another name & email id will lead to disqualification. The winner will be announced after profile verification. Once you're a winner, you will not be considered for the prizes for another two months. Note: You can participate only 1 time.

52

52

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for DEXILANT Dexilant is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from four suppliers.

59

59

Pharmacy Joe

APRIL 14, 2024

In this episode, I’ll discuss the efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease. Episode 913: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease? Subscribe on iTunes , Android , or Stitcher The prescribing information for apixaban recommends not reducing the dose when being used in patients with end-stage renal disease and atrial fibrillation.

Inpatient 52

Inpatient Dosage 52

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for FARXIGA Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from five suppliers.

59

59

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmacy Times

APRIL 14, 2024

Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.

58

58

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for TAGRISSO Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier.

59

59

The Guardian - Pharmaceutical Industry

APRIL 14, 2024

Exclusive: contaminated blood campaigners say internal 1976 Immuno AG document proves British government negligence Analysis: families hope report will finally apportion blame The British government was willing to risk infecting NHS patients to get “lower-priced” blood products, according to a document that campaigners claim proves state and corporate guilt in one of the country’s worst ever scandals.

Documentation 143

Documentation 143

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for EPRONTIA Eprontia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier.

59

59

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Drug Patent Watch

APRIL 14, 2024

This chart shows the pharmaceutical companies with the most patents in New Zealand.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52